Summary Clinical Evaluation of Carisbamate for Adjunctive Use in Treatment of Partial Onset Seizures

Size: px
Start display at page:

Download "Summary Clinical Evaluation of Carisbamate for Adjunctive Use in Treatment of Partial Onset Seizures"

Transcription

1 Summary Clinical Evaluation of Carisbamate for Adjunctive Use in Treatment of Partial Onset Seizures J&J Pharmaceutical R&D Antiepileptic Drug Trials XI April

2 Summary of Past Development Efficacy in preclinical models and Phase 2 clinical trials provided evidence that carisbamate (CRS) has anticonvulsant effects that might extend across a broad range of seizure types CRS was in licensed from SK Life Sciences and J&J PRD commenced its full development as an adjunctive treatment of partial onset seizures in adults 4 randomized double blind placebo controlled trials were executed between Feb 2005 and Dec 2009 CRS failed to demonstrate a consistent pattern of superior efficacy across the dosage ranges studied in this group of patients, and further development in this indication was discontinued by J&J PRD 2

3 Current Status of Carisbamate Carisbamate has been returned to SK Life Science SK will continue the development of CRS in epilepsy and in other indications SK will continue to supply 3 subjects remaining in an expanded access program 3

4 Carisbamate Efficacy in Phase 2 = p<0.05 4

5 Efficacy in Two Trials in a Lower Dose Range = p<0.05 5

6 Efficacy in a Higher Dose Range = p<0.05 6

7 Efficacy by Induction Status EPY 2003 EPY 3001/3002 EPY 3013 Induced = receiving Barbiturate, Phenytoin, or Carbamazepine 7

8 Design of Clinical Trials EPY 2003 EPY 3001 EPY 3002 EPY 3013 Dosages Pbo, 100, 300, 800, 1600 mg/d Pbo, 200, 400 mg/d Pbo, 200, 400 mg/d Pbo, 800, 1200 mg/d N Subjects Titration 4w None None 2w Maintenance 12w 12w 12w 12w Age >18, <70 >16 >16 >16 Min Prior AED Max Concom AED Other Excl >100 sz/m at BL 8

9 Demographics EPY 2003 EPY 3001 EPY 3002 EPY 3013 Regions NA, SA, EU NA, SA, EU, AS NA, SA, EU, AS NA, EU, AS, AUS # Sites N Subjects Male, n (%) Race White Black 3 1 <1 1 Asian > Other 2 1 <1 4 Age, Median (Range) 37 (17 69) 33 (16 75) 34 (16 74) 36 (16 73)

10 Baseline Disease Characteristics EPY 2003 EPY 3001 EPY 3002 EPY 3013 Years Since Diagnosis, Median (Range) 21 (0 58) 19 (1 57) 15 (1 62) 18 (1 61) Prior AEDs, Median (Range) 6 (2 18) 5 (1 24) 4 (1 17) 6 (1 22) Baseline Monthly POS, Median (Range) 10.5 (3 445) 9 (2 614) 7 (2 274) 8 (3 110) Number of Co AEDs, % One Two Three % Induced Syndrome, % Symptomatic Cryptogenic Undetermined < <

11 Factors Examined in Relation to Efficacy Age and Gender Geographic Region Duration of Epilepsy Number of Prior AEDs Number of Concurrent AEDs Etiology (Symptomatic/Cryptogenic) Baseline Seizure Rate 11

12 Baseline Factors Not Predictive of Placebo Response STUDY ID EPILEPTIC SYNDROMES CLASS UNIQUE SITE NAME CP SEIZURES PRESENT IN BASELINE SIZE OF STUDY SITE SPM SEIZURES PRESENT IN BASELINE RECURITMENT RATE AT SITE SECONDARY GEN SEIZURES PRESENT COUNTRY GTC SEIZURES PRESENT IN BASELINE OTHER SEIZURE TYPES PRESENT AGE in YEARS BASELINE POS RATE BODY MASS_INDEX RACE HADS BASELINE ANXIETY SCORE SEX HADS BASELINE DEPRESSION SCORE WEIGHT QOLIE 31 BASELINE TOTAL SCORE SZ SEVERITY BASELINE RECOVERY SCORE AGE IN YEARS AT EPILEPSY DIAGNOS IS THERE FAMILY HISTORY OF EPILEPSY DATE OF RANDOMIZATION HAS SUBJECT EVER HAD STATUS EPILEPTICUS SUBJECT DB PHASE COMPLETION EPILEPSY SURGERY IN PRIOR HISTORY NUMBER OF PRIOR REPORTED AEDS PHENOBARBITAL IN PRIOR HISTORY CARBAMAZEPINE IN PRIOR HISTORY 12

13 Past Performance Was Not Predictive Only the best sites in Phase 2 were invited to participate in Phase 3

14 Seizure Reduction for Carisbamate not Related to Placebo Response Sites Grouped in Order of Placebo Response Quartile Pooled Studies EPY

15 EPY 2003 ITT: Median Percent Reduction From Baseline Over Time in POS Frequency Observed Cases 300mg 100mg Placebo

16 EPY 3001 ITT: Median Percent Reduction From Baseline Over Time in POS Frequency Observed Cases 400mg 200mg Placebo

17 EPY 3002 ITT: Median Percent Reduction From Baseline Over Time in POS Frequency Observed Cases 400mg 200mg Placebo

18 EPY 3013 ITT: Median Percent Reduction From Baseline Over Time in POS Frequency Observed Cases Median Percent Reduction from Baseline 1200mg 800mg Placebo Week of DB Phase 18

19 Why is it so difficult to develop an AED as an adjunct in the treatment of partial onset seizures? STRICTLY CONFIDENTIAL 19

20 Some Basic Requirements Subjects Sites Sponsors STRICTLY CONFIDENTIAL 20

21 Requirements: the Subject Must have epilepsy Must have POS Must know when he has had a seizure Must record seizures consistently over 5+ months Must take study drugs Must report other meds 21

22 Requirements: the Investigator Must be able to diagnose and classify seizures Must recognize the capable subject Must assure continuity and consistency of assessors Must provide appropriate support and encouragement to the subject Must comply with the protocol, report data accurately and in a timely manner 22

23 Requirements: the Sponsor Must choose appropriate sites and investigators Must communicate the key requirements of the protocol and answer the investigators questions promptly Must monitor: Site compliance, especially early in trial Individual and tabulated summary data in real time 23

NASDAQ: ZGNX. Company Presentation. October 2017

NASDAQ: ZGNX. Company Presentation. October 2017 NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking

More information

2. SYNOPSIS Name of Sponsor/Company:

2. SYNOPSIS Name of Sponsor/Company: in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Efficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials

Efficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials Epilepsia, 42(Suppl. 4):31 35, 2001 Blackwell Science, Inc. International League Against Epilepsy Efficacy of : A Review of Three Pivotal Clinical Trials Michael Privitera University of Cincinnati Medical

More information

eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd

eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd 8 October 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards

More information

JBPOS0101: A New Generation mglur- and BBB- Targeted AED for the Treatment of Super-Refractory Status Epilepticus (SRSE)

JBPOS0101: A New Generation mglur- and BBB- Targeted AED for the Treatment of Super-Refractory Status Epilepticus (SRSE) JBPOS0101: A New Generation mglur- and BBB- Targeted AED for the Treatment of Super-Refractory Status Epilepticus (SRSE) Bio-Pharm Solutions Co., Ltd. Yongho Kwak, Ph.D. Director of Pharmacology 1 Who

More information

Epilepsy and EEG in Clinical Practice

Epilepsy and EEG in Clinical Practice Mayo School of Professional Development Epilepsy and EEG in Clinical Practice November 10-12, 2016 Hard Rock Hotel at Universal Orlando Orlando, FL Course Directors Jeffrey Britton, MD and William Tatum,

More information

New Drug Evaluation: brivaracetam [tablet and solution, oral; solution, intravenous]

New Drug Evaluation: brivaracetam [tablet and solution, oral; solution, intravenous] Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

New Medicines Profile

New Medicines Profile New Medicines Profile February 2010 Issue No. 10/02 Eslicarbazepine Concise evaluated information to support the managed entry of new medicines in the NHS Brand Name, (Manufacturer): Zebinix (Eisai Limited)

More information

Successful treatment of super-refractory tonic status epilepticus with rufinamide: first clinical report

Successful treatment of super-refractory tonic status epilepticus with rufinamide: first clinical report *Manuscript Click here to view linked References Successful treatment of super-refractory tonic status epilepticus with rufinamide: first clinical report Thompson AGB 1, Cock HR 1,2. 1 St George s University

More information

London, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION

London, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION London, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION 1/15 EMEA 2006 1. Introduction Epilepsy is one of the most common and challenging neurological disorders.

More information

Note: Repository Corticotropin Injection (ACTH Gel, H.P. Acthar Gel) is addressed in medical policy

Note: Repository Corticotropin Injection (ACTH Gel, H.P. Acthar Gel) is addressed in medical policy Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd

levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd Scottish Medicines Consortium Resubmission levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd 11 January 2008 The Scottish Medicines

More information

Opinion 24 July 2013

Opinion 24 July 2013 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 FYCOMPA 2 mg, film-coated tablet B/7 (CIP: 34009 267 760 0 8) B/28 (CIP: 34009 268 447 4 5) FYCOMPA 4

More information

STUDY 1 PHASE 3 TOP-LINE RESULTS. September 2017

STUDY 1 PHASE 3 TOP-LINE RESULTS. September 2017 STUDY 1 PHASE 3 TOP-LINE RESULTS September 2017 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking

More information

6 semanas de embarazo. Topamax effect potassium level. Inicio / Embarazo / 6 semanas de embarazo

6 semanas de embarazo. Topamax effect potassium level. Inicio / Embarazo / 6 semanas de embarazo Inicio / Embarazo / 6 semanas de embarazo 6 semanas de embarazo Topamax effect potassium level Dec 16, 2009. Since the effects of topiramate on acid-base balance and potassium levels have not been well

More information

Ganaxolone as a Treatment for Drug-Resistant Epilepsy in Children

Ganaxolone as a Treatment for Drug-Resistant Epilepsy in Children Ganaxolone as a Treatment for Drug-Resistant Epilepsy in Children ANTIEPILEPTIC DRUG and DEVICE TRIALS XIII May 13-15, 2015 Turnberry Isle Miami Hotel Gail M. Farfel, PhD Chief Development & Regulatory

More information

Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome

Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium

More information

TRANSPARENCY COMMITTEE OPINION. 19 July 2006

TRANSPARENCY COMMITTEE OPINION. 19 July 2006 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated

More information

New drugs necessity for therapeutic drug monitoring

New drugs necessity for therapeutic drug monitoring New drugs necessity for therapeutic drug monitoring Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital Basel kraehenbuehl@uhbs.ch Drugs suitable for TDM Narrow therapeutic range

More information

Canadian Expert Drug Advisory Committee Final Recommendation Plain Language Version

Canadian Expert Drug Advisory Committee Final Recommendation Plain Language Version Canadian Expert Drug Advisory Committee Final Recommendation Plain Language Version LACOSAMIDE (Vimpat UCB Canada Inc.) Indication: Epilepsy, Partial-Onset Seizures Recommendation: The Canadian Expert

More information

mg 25 mg mg 25 mg mg 100 mg 1

mg 25 mg mg 25 mg mg 100 mg 1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Author(s): C. James Holliman, M.D. (Penn State University), 2008

Author(s): C. James Holliman, M.D. (Penn State University), 2008 Project: Ghana Emergency Medicine Collaborative Document Title: Status Epilepticus (SE) Author(s): C. James Holliman, M.D. (Penn State University), 2008 License: Unless otherwise noted, this material is

More information

Unit VIII Problem 7 Pharmacology: Principles of Management of Seizure Disorders

Unit VIII Problem 7 Pharmacology: Principles of Management of Seizure Disorders Unit VIII Problem 7 Pharmacology: Principles of Management of Seizure Disorders - Terminologies: Anti-convulsants: they are used to control convulsions seen in certain types of epilepsy. Convulsions may

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 05 May 2010 LAMICTAL 2 mg, dispersible / chewable tablet B/30 (CIP: 354 581-7) LAMICTAL 5 mg, dispersible / chewable

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

M. Sillanpää a, D. Schmidt b, * Received 27 January 2006; revised 28 February 2006; accepted 28 February 2006 Available online 17 April 2006

M. Sillanpää a, D. Schmidt b, * Received 27 January 2006; revised 28 February 2006; accepted 28 February 2006 Available online 17 April 2006 Epilepsy & Behavior 8 (2006) 713 719 www.elsevier.com/locate/yebeh Prognosis of seizure recurrence after stopping antiepileptic drugs in seizure-free patients: A long-term population-based study of childhood-onset

More information

Epilepsy and Epileptic Seizures

Epilepsy and Epileptic Seizures Epilepsy and Epileptic Seizures Petr Marusič Dpt. of Neurology Charles University, Second Faculty of Medicine Motol University Hospital Diagnosis Steps Differentiation of nonepileptic events Seizure classification

More information

New antiepileptic drugs

New antiepileptic drugs Chapter 29 New antiepileptic drugs J.W. SANDER UCL Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London, and Epilepsy Society, Chalfont

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Pujar SS, Martinos MM, Cortina-Borja M, et

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive

More information

The following page contains the final YODA Project review approving this proposal.

The following page contains the final YODA Project review approving this proposal. The YODA Project Research Proposal Review The following page contains the final YODA Project review approving this proposal. The Yale University Open Data Access (YODA) Project Yale University Center for

More information

Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities

Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities Seizure 004; : 68 75 doi:0.06/s059-(0)0054-7 Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities B. HUBER, W. BÖMMEL, I. HAUSER, V. HORSTMANN,

More information

Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act

Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act This guidance is intended for Coventry and Warwickshire Partnership Trust staff to use when

More information

Refractory Status Epilepticus in Children: What are the Options?

Refractory Status Epilepticus in Children: What are the Options? Refractory Status Epilepticus in Children: What are the Options? Weng Man Lam, PharmD, BCPS, BCPPS PICU Clinical Pharmacy Specialist Memorial Hermann Texas Medical Center November 11, 2017 Objectives 1.

More information

When to start, which drugs and when to stop

When to start, which drugs and when to stop When to start, which drugs and when to stop Dr. Suthida Yenjun, MD. PMK Epilepsy Annual Meeting 2016 The main factors to consider in making the decision The risk for recurrent seizures, which varies based

More information

Topiramate in clinical practice: first year s postlicensing experience in a specialist epilepsy clinic

Topiramate in clinical practice: first year s postlicensing experience in a specialist epilepsy clinic J Neurol Neurosurg Psychiatry 1999;66:759 763 759 The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool L9 7LJ, UK M W Kellett D F Smith P A Stockton D W Chadwick Correspondence to: Dr

More information

5.9. Rehabilitation to Improve Central Pain

5.9. Rehabilitation to Improve Central Pain 5.9. Rehabilitation to Improve Central Pain Evidence Tables and References Canadian Best Practice Recommendations for Stroke Care 2011-2013 Update Last Updated: June 25 th, 2013 Contents Search Strategy...

More information

Refractory epilepsy: treatment with new antiepileptic drugs

Refractory epilepsy: treatment with new antiepileptic drugs Seizure 2000; 9: 51 57 doi: 10.1053/seiz.1999.0348, available online at http://www.idealibrary.com on Refractory epilepsy: treatment with new antiepileptic drugs P. K. DATTA & P. M. CRAWFORD Department

More information

Int.J.Curr.Res.Aca.Rev.2016; 4(7): 32-37

Int.J.Curr.Res.Aca.Rev.2016; 4(7): 32-37 Evaluation of Clinical Outcome, Drug Utilization and Effect on Liver Enzymes of Anti-epileptics in Epileptic Patients Mathew George 1, Lincy Joseph 2, Robert Mathew 3 and Preethi Christina Jose 4 * 1 Department

More information

Gabapentin as an antiepileptic drug in man

Gabapentin as an antiepileptic drug in man Journal of Neurology, Neurosurgery, and Psychiatry 1987;50:682-686 Gabapentin as an antiepileptic drug in man P CRAWFORD, E GHADAL, R LANE, L BLUMHARDT, D CHADWCK From the Department ofneurology, Walton

More information

Lamictal (Epilepsy) Forecast and Market Analysis to Reference Code: GDHC1062DFR Publication Date: February 2013

Lamictal (Epilepsy) Forecast and Market Analysis to Reference Code: GDHC1062DFR Publication Date: February 2013 Lamictal (Epilepsy) Forecast and Market Analysis to 2022 Reference Code: GDHC1062DFR Publication Date: February 2013 Executive Summary Lamictal (lamotrigine) Key Metrics in the Nine Major Pharmaceutical

More information

Shared Care Guideline Stiripentol use for SCN1A related and Severe Myoclonic Epilepsies in Infancy

Shared Care Guideline Stiripentol use for SCN1A related and Severe Myoclonic Epilepsies in Infancy Shared Care Guideline Stiripentol use for SCN1A related and Severe Myoclonic Epilepsies in Infancy Executive Summary 1. Indication Stiripentol is indicated for use in conjunction with clobazam and valproate

More information

Ernie Somerville Prince of Wales Hospital EPILEPSY

Ernie Somerville Prince of Wales Hospital EPILEPSY Ernie Somerville Prince of Wales Hospital EPILEPSY Overview Classification New and old anti-epileptic drugs (AEDs) Neuropsychiatric side-effects Limbic encephalitis Non-drug therapies Therapeutic wishlist

More information

2015 Fall CE for the Upstate 9/20/2015. Seizure Management in the Dog: Options Beyond Phenobarbital

2015 Fall CE for the Upstate 9/20/2015. Seizure Management in the Dog: Options Beyond Phenobarbital Seizure Management in the Dog: Options Beyond Phenobarbital Upstate Veterinary Specialists Fall 2015 CE September 20, 2015 Rennie Waldron, DVM, DACVIM (Neurology) Objective Outline Zonisamide, Levetiracetam

More information

DEFINITION AND CLASSIFICATION OF EPILEPSY

DEFINITION AND CLASSIFICATION OF EPILEPSY DEFINITION AND CLASSIFICATION OF EPILEPSY KAMORNWAN KATANYUWONG MD. 7 th epilepsy camp : Bang Saen, Thailand OUTLINE Definition of epilepsy Definition of seizure Definition of epilepsy Epilepsy classification

More information

Adjunctive perampanel for refractory partial-onset seizures Randomized phase III study 304

Adjunctive perampanel for refractory partial-onset seizures Randomized phase III study 304 Adjunctive perampanel for refractory partial-onset seizures Randomized phase III study 304 Jacqueline A. French, MD Gregory L. Krauss, MD Victor Biton, MD David Squillacote, MD Haichen Yang, MD Antonio

More information

2 nd Line Treatments for Dravet. Eric BJ Ségal, MD Northeast Regional Epilepsy Group

2 nd Line Treatments for Dravet. Eric BJ Ségal, MD Northeast Regional Epilepsy Group 2 nd Line Treatments for Dravet Eric BJ Ségal, MD Northeast Regional Epilepsy Group Disclosures Accepted honoraria from Greenwich Pharmaceuticals, Zogenix, Eisai, Lundbeck, Lineagen. Overview Evidence

More information

Clinical Policy: Vigabatrin (Sabril) Reference Number: CP.PHAR.169 Effective Date: 02/16

Clinical Policy: Vigabatrin (Sabril) Reference Number: CP.PHAR.169 Effective Date: 02/16 Clinical Policy: (Sabril) Reference Number: CP.PHAR.169 Effective Date: 02/16 Last Review Date: 02/17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

More information

Pharmacological Treatment of Non-Lesional Epilepsy December 8, 2013

Pharmacological Treatment of Non-Lesional Epilepsy December 8, 2013 Pharmacological Treatment of Non-Lesional Epilepsy December 8, 2013 Michael Privitera, MD Professor of Neurology University of Cincinnati, Neuroscience Institute American Epilepsy Society Annual Meeting

More information

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE. Final Appraisal Determination. Newer drugs for epilepsy in children

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE. Final Appraisal Determination. Newer drugs for epilepsy in children NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guidance 1.1 The newer antiepileptic drugs gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, and vigabatrin (as an adjunctive therapy for partial

More information

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,

More information

Status Epilepticus: Implications Outside the Neuro-ICU

Status Epilepticus: Implications Outside the Neuro-ICU Status Epilepticus: Implications Outside the Neuro-ICU Jeffrey M Singh MD Critical Care and Neurocritical Care Toronto Western Hospital October 31 st, 2014 Disclosures I (unfortunately) have no disclosures

More information

PHA5128 Dose Optimization II Case Study 3 Spring 2013

PHA5128 Dose Optimization II Case Study 3 Spring 2013 Use the vancomycin dosing nomogram table below: A female patient, 57 years of age, 5 6 in height and 100 in weight had an infection requiring vancomycin treatment. Her serum creatinine was 0.8 mg/d. What

More information

Review of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP

Review of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP Review of Anticonvulsant Medications: Traditional and Alternative Uses Andrea Michel, PharmD, CACP Objectives Review epidemiology of epilepsy Classify types of seizures Discuss non-pharmacologic and pharmacologic

More information

GABAPENTIN BNF Gabapentin is a chemical analogue of γ-aminobutyric acid (GABA) but does not act

GABAPENTIN BNF Gabapentin is a chemical analogue of γ-aminobutyric acid (GABA) but does not act GABAPENTIN BNF 4.8.1 Class: Anti-epileptic. Indications: Adjunctive treatment for partial seizures with or without secondary generalisation; 1,2 neuropathic pain of any cause. 3 12 Pharmacology Gabapentin

More information

ORIGINAL CONTRIBUTION

ORIGINAL CONTRIBUTION Epilepsy in Childhood An Audit of Clinical Practice ORIGINAL CONTRIBUTION Hans A. Carpay, MD; Willem F. M. Arts, MD, PhD; Ada T. Geerts, MSc; Hans Stroink, MD; Oebele F. Brouwer, MD, PhD; A. C. Boudewyn

More information

Proceedings of the World Small Animal Veterinary Association Mexico City, Mexico 2005

Proceedings of the World Small Animal Veterinary Association Mexico City, Mexico 2005 Close this window to return to IVIS Proceedings of the World Small Animal Veterinary Association Mexico City, Mexico 2005 Hosted by: Reprinted in the IVIS website with the permission of the WSAVA anticonvulsant

More information

Tailoring therapy to optimize care for Epilepsy. Dr Tim Wehner National Hospital for Neurology and Neurosurgery London, UK For discussion only

Tailoring therapy to optimize care for Epilepsy. Dr Tim Wehner National Hospital for Neurology and Neurosurgery London, UK For discussion only Tailoring therapy to optimize care for Epilepsy Dr Tim Wehner National Hospital for Neurology and Neurosurgery London, UK For discussion only Disclosures Session (travel expenses) sponsored by Pfizer Premature

More information

Abbreviated Update: Oral Anticonvulsants New Drug: ezogabine (Potiga)

Abbreviated Update: Oral Anticonvulsants New Drug: ezogabine (Potiga) Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

PFIZER INC. Study Initiation Date and Primary Completion or Completion Dates: 11 November 1998 to 17 September 1999

PFIZER INC. Study Initiation Date and Primary Completion or Completion Dates: 11 November 1998 to 17 September 1999 PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Lacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011

Lacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011 Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a

More information

GW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy

GW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy December 7, 2015 GW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy As previously announced, seven posters

More information

Epilepsy. Seizures and Epilepsy. Buccal Midazolam vs. Rectal Diazepam for Serial Seizures. Epilepsy and Seizures 6/18/2008

Epilepsy. Seizures and Epilepsy. Buccal Midazolam vs. Rectal Diazepam for Serial Seizures. Epilepsy and Seizures 6/18/2008 Seizures and Epilepsy Paul Garcia, M.D. UCSF Epilepsy Epileptic seizure: the physical manifestation of aberrant firing of brain cells Epilepsy: the tendency to recurrent, unprovoked epileptic seizures

More information

Lyrica. Lyrica, Lyrica CR (pregabalin) Description

Lyrica. Lyrica, Lyrica CR (pregabalin) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.18 Subject: Page: 1 of 7 Last Review Date: March 16, 2018 Description, CR (pregabalin) Background

More information

ESCA: Cinacalcet (Mimpara )

ESCA: Cinacalcet (Mimpara ) ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details

More information

ACTH therapy for generalized seizures other than spasms

ACTH therapy for generalized seizures other than spasms Seizure (2006) 15, 469 475 www.elsevier.com/locate/yseiz ACTH therapy for generalized seizures other than spasms Akihisa Okumura a,b, *, Takeshi Tsuji b, Toru Kato b, Jun Natsume b, Tamiko Negoro b, Kazuyoshi

More information

Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine

Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2016 Concomitant administration of rifampicin and oxcarbazepine results in

More information

Risk of seizure recurrence after antiepileptic drug withdrawal, an Indian study

Risk of seizure recurrence after antiepileptic drug withdrawal, an Indian study Neurology Asia 2006; 11 : 19 23 Risk of seizure recurrence after antiepileptic drug withdrawal, an Indian study Archana VERMA DM (Neurology) MD, Surendra MISRA DM (Neurology) FRCP (Edin) Department of

More information

Improving trial methodology: Examples from epilepsy. Tony Marson University of Liverpool

Improving trial methodology: Examples from epilepsy. Tony Marson University of Liverpool Improving trial methodology: Examples from epilepsy Tony Marson University of Liverpool This talk Examples of trial methodology research Focus on epilepsy but Examples are relevant to any field Epilepsy

More information

PREVALENCE & TREATMENT OF PATIENTS WITH EPILEPSY ASSOCIATED WITH INTELLECTUAL DISABILITY: A PILOT STUDY IN PALESTINE

PREVALENCE & TREATMENT OF PATIENTS WITH EPILEPSY ASSOCIATED WITH INTELLECTUAL DISABILITY: A PILOT STUDY IN PALESTINE Vol.4, No., P.83-89, 006, ISSN 76-6807, http//www.iugzaza.edu.ps/ara/research/ PREVALENCE & TREATMENT OF PATIENTS WITH EPILEPSY ASSOCIATED WITH INTELLECTUAL DISABILITY: A PILOT STUDY IN PALESTINE Waleed

More information

Chris Rundfeldt 1,4*, Andrea Tipold 2,3 and Wolfgang Löscher 3,4

Chris Rundfeldt 1,4*, Andrea Tipold 2,3 and Wolfgang Löscher 3,4 Rundfeldt et al. BMC Veterinary Research (2015) 11:228 DOI 10.1186/s12917-015-0548-9 RESEARCH ARTICLE Open Access Efficacy, safety, and tolerability of imepitoin in dogs with newly diagnosed epilepsy in

More information

Successful re-introduction of lamotrigine after initial rash

Successful re-introduction of lamotrigine after initial rash Seizure 2000; 9: 282 286 doi: 10.1053/seiz.2000.0394, available online at http://www.idealibrary.com on Successful re-introduction of lamotrigine after initial rash F. M. C. BESAG, G. Y. T. NG & F. POOL

More information

Cannabis Use in Epilepsy: Parent & Scientist Weighs In. Catherine Jacobson, PhD Director, Clinical Research

Cannabis Use in Epilepsy: Parent & Scientist Weighs In. Catherine Jacobson, PhD Director, Clinical Research Cannabis Use in Epilepsy: Parent & Scientist Weighs In Catherine Jacobson, PhD Director, Clinical Research Professional Background PhD, Neuroscience, Oregon Health & Science University Post-doctoral Fellowship,

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Absence seizures, 6 in childhood, 95 Adults, seizures and status epilepticus in, management of, 34 35 with first-time seizures. See Seizure(s),

More information

Prescribing and Monitoring Anti-Epileptic Drugs

Prescribing and Monitoring Anti-Epileptic Drugs Prescribing and Monitoring Anti-Epileptic Drugs Mark Granner, MD Clinical Professor and Vice Chair for Clinical Programs Director, Iowa Comprehensive Epilepsy Program Department of Neurology University

More information

APPENDIX K Pharmacological Management

APPENDIX K Pharmacological Management 1 2 3 4 APPENDIX K Pharmacological Management Table 1 AED options by seizure type Table 1 AED options by seizure type Seizure type First-line AEDs Adjunctive AEDs Generalised tonic clonic Lamotrigine Oxcarbazepine

More information

Defining refractory epilepsy

Defining refractory epilepsy Defining refractory epilepsy Pasiri S, PMK Hospital @ 8.30 9.00, 23/7/2015 Nomenclature Drug resistant epilepsy Medically refractory epilepsy Medical intractable epilepsy Pharmacoresistant epilepsy 1 Definition

More information

Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study

Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study Seizure 2000; 9: 224 232 doi: 10.1053/seiz.2000.0381, available online at http://www.idealibrary.com on Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled

More information

Sponsor Novartis. Generic Drug Name. Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title

Sponsor Novartis. Generic Drug Name. Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title Sponsor Novartis Generic Drug Name Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title A randomized, double-blind, multi-center, active-controlled, parallel

More information

Outline. What is a seizure? What is epilepsy? Updates in Seizure Management Terminology, Triage & Treatment

Outline. What is a seizure? What is epilepsy? Updates in Seizure Management Terminology, Triage & Treatment Outline Updates in Seizure Management Terminology, Triage & Treatment Joseph Sullivan, MD! Terminology! Videos of different types of seizures! Diagnostic evaluation! Treatment options! Acute! Maintenance

More information

PEDIATRIC PHARMACOTHERAPY

PEDIATRIC PHARMACOTHERAPY PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the Children s Medical Center at the University of Virginia Volume 7 Number 11 November 2001 A Oxcarbazepine Use in Children

More information

Epilepsy 7/28/09! Definitions. Classification of epilepsy. Epidemiology of Seizures and Epilepsy. International classification of epilepsies

Epilepsy 7/28/09! Definitions. Classification of epilepsy. Epidemiology of Seizures and Epilepsy. International classification of epilepsies Definitions Epilepsy Dr.Yotin Chinvarun M.D., Ph.D. Seizure: the clinical manifestation of an abnormal and excessive excitation of a population of cortical neurons Epilepsy: a tendency toward recurrent

More information

Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation).

Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation). TITLE OF THE THESIS / RESEARCH: Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation). INTRODUCTION: Epilepsy is a common chronic neurological disorder characterized

More information

Epilepsy Specialist Symposium Treatment Algorithms in the Diagnosis and Treatment of Epilepsy

Epilepsy Specialist Symposium Treatment Algorithms in the Diagnosis and Treatment of Epilepsy Epilepsy Specialist Symposium Treatment Algorithms in the Diagnosis and Treatment of Epilepsy November 30, 2012 Fred Lado, MD, Chair Montefiore Medical Center Albert Einstein College of Medicine Bronx,

More information

Idiopathic Epileptic Syndromes

Idiopathic Epileptic Syndromes Idiopathic Epileptic Syndromes Greek words idios = self, own and personal pathic = suffer Kamornwan Katanuwong MD Chiangmai University Hospital 1 st Epilepsy Camp, Hua Hin 20 th August 2010 Is a syndrome

More information

Bournemouth, Dorset and Poole Prescribing Forum

Bournemouth, Dorset and Poole Prescribing Forum SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for

More information

Trial No.: RIS-USA-102 Clinical phase: III

Trial No.: RIS-USA-102 Clinical phase: III SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:

More information

Patients with generalised epilepsy have a higher white blood cell count than patients with focal epilepsy

Patients with generalised epilepsy have a higher white blood cell count than patients with focal epilepsy Original article Epileptic Disord 2012; 14 (1): 57-63 Patients with generalised epilepsy have a higher white blood cell count than patients with focal epilepsy Rani A Sarkis 1, Lara Jehi 1, Diosely Silveira

More information

SYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER

SYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances

More information

Can t Stop the Seizing!

Can t Stop the Seizing! Can t Stop the Seizing! Joseph Miller, MD, MS MCEP Critical Care March, 2019 Objectives Describe the importance of time to treatment Delineate treatment based on best evidence Describe novel diagnostic

More information

11/7/2018 EPILEPSY UPDATE. Dr.Ram Sankaraneni. Disclosures. Speaker bureau LivaNova

11/7/2018 EPILEPSY UPDATE. Dr.Ram Sankaraneni. Disclosures. Speaker bureau LivaNova EPILEPSY UPDATE Dr.Ram Sankaraneni Disclosures Speaker bureau LivaNova 1 Outline New onset Seizure Investigations in patients with epilepsy Medical management of epilepsy Non Pharmacological options in

More information

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016 BioPortfolio has been marketing business

More information

Somnolence and Sedation Were Transient Adverse Events for Most Patients Receiving Clobazam Therapy: Post Hoc Analysis of Trial OV-1012 Data

Somnolence and Sedation Were Transient Adverse Events for Most Patients Receiving Clobazam Therapy: Post Hoc Analysis of Trial OV-1012 Data Elmer ress Short Communication J Neurol Res. 2015;5(4-5):252-256 Somnolence and Sedation Were Transient Adverse Events for Most Patients Receiving Clobazam Therapy: Post Hoc Analysis of Trial OV-1012 Data

More information

TRANSPARENCY COMMITTEE OPINION. 9 May 2007

TRANSPARENCY COMMITTEE OPINION. 9 May 2007 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2007 LYRICA 25 mg capsules Pack of 56 capsules (CIP: 365 127-0) Pack of 84 capsules (CIP: 365 135-3) Pack of

More information

Page 1. Date & Sign when teaching done. Teaching Aids Used

Page 1. Date & Sign when teaching done. Teaching Aids Used Page 1 receive as outlined. Any additional, as determined by the medical team, may be added as required. A. If the child has had a febrile seizure: 1. In preparation for discharge, the nurse will review

More information

NASDAQ: ZGNX Corporate Update

NASDAQ: ZGNX Corporate Update NASDAQ: ZGNX Corporate Update June 2016 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking

More information